{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T23:28:39Z","timestamp":1716679719482},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,5,21]],"date-time":"2008-05-21T00:00:00Z","timestamp":1211328000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Abdom Imaging"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00261-008-9410-x","type":"journal-article","created":{"date-parts":[[2008,5,20]],"date-time":"2008-05-20T10:49:41Z","timestamp":1211280581000},"page":"297-302","source":"Crossref","is-referenced-by-count":7,"title":["Crohn\u2019s disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know"],"prefix":"10.1007","volume":"34","author":[{"given":"David H.","family":"Bruining","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,21]]},"reference":[{"key":"9410_CR1","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","volume":"126","author":"EV Loftus Jr","year":"2004","unstructured":"Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504\u20131517","journal-title":"Gastroenterology"},{"key":"9410_CR2","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","volume":"12","author":"KS Rothfuss","year":"2006","unstructured":"Rothfuss KS, Stange EF, Herrlinger KR (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12:4819\u20134831","journal-title":"World J Gastroenterol"},{"issue":"11","key":"9410_CR3","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1086\/520732","volume":"28","author":"L Benson","year":"2007","unstructured":"Benson L, Song X, Campos J, Singh N (2007) Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 28(11):1233\u20131235","journal-title":"Infect Control Hosp Epidemiol"},{"key":"9410_CR4","first-page":"449","volume":"96","author":"IE Koutroubakis","year":"2001","unstructured":"Koutroubakis IE, Petinaki E, Mouzas IA, et\u00a0al. (2001) Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 96:449\u2013454","journal-title":"Am J Gastroenterol"},{"key":"9410_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/gut.42.6.788","volume":"42","author":"JF Quinton","year":"1998","unstructured":"Quinton JF, Sendid B, Reumaux D, et\u00a0al. (1998) Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42:788\u2013791","journal-title":"Gut"},{"key":"9410_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00054725-200108000-00003","volume":"7","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Loftus EV Jr, Colombel JF, et\u00a0al. (2001) Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn\u2019s disease. Inflamm Bowel Dis 7:192\u2013201","journal-title":"Inflamm Bowel Dis"},{"key":"9410_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1572-0241.2001.03613.x","volume":"96","author":"M Peeters","year":"2001","unstructured":"Peeters M, Joossens S, Vermeire S, et\u00a0al. (2001) Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 96:730\u2013734","journal-title":"Am J Gastroenterol"},{"key":"9410_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/00042737-200209000-00013","volume":"14","author":"RK Linskens","year":"2002","unstructured":"Linskens RK, Mallant-Hent RC, Groothuismink ZM, et\u00a0al. (2002) Evaluation of serological markers to differentiate between ulcerative colitis and Crohn\u2019s disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol 14:1013\u20131018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9410_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1572-0241.2006.00475.x","volume":"101","author":"GL Austin","year":"2006","unstructured":"Austin GL, Shaheen NJ, Sandler RS (2006) Positive and negative predictive values: use of inflammatory bowel disease serologic markers. Am J Gastroenterol 101:413\u2013416","journal-title":"Am J Gastroenterol"},{"key":"9410_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1572-0241.2006.00456.x","volume":"101","author":"MC Dubinsky","year":"2006","unstructured":"Dubinsky MC, Lin YC, Dutridge D, et\u00a0al. (2006) Serum immune responses predict rapid disease progression among children with Crohn\u2019s disease: immune responses predict disease progression. Am J Gastroenterol 101:360\u2013367","journal-title":"Am J Gastroenterol"},{"key":"9410_CR11","first-page":"A-650","volume":"132","author":"DH Bruining","year":"2007","unstructured":"Bruining DH, Siddiki H, Fletcher JG, et\u00a0al. (2007) Prevalence of penetrating disease and extraintestinal manifestations of Crohn\u2019s disease detected with CT enterography {abstract}. Gastroenterology 132:A-650","journal-title":"Gastroenterology"},{"key":"9410_CR12","unstructured":"Solem C, Loftus EV, Fletcher JG, et\u00a0al. (2008) Small bowel imaging in Crohn\u2019s disease (CD): a prospective, blinded, 4-way comparison trial. Gastrointest Endosc in press"},{"key":"9410_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1148\/radiol.2382041159","volume":"238","author":"KD Bodily","year":"2006","unstructured":"Bodily KD, Fletcher JG, Solem CA, et\u00a0al. (2006) Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography\u2014correlation with endoscopic and histologic findings of inflammation. Radiology 238:505\u2013516","journal-title":"Radiology"},{"key":"9410_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1148\/radiol.2413051444","volume":"241","author":"F Booya","year":"2006","unstructured":"Booya F, Fletcher JG, Huprich JE, et\u00a0al. (2006) Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology 241:787\u2013795","journal-title":"Radiology"},{"key":"9410_CR15","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/gut.2005.084301","volume":"55","author":"JF Colombel","year":"2006","unstructured":"Colombel JF, Solem CA, Sandborn WJ, et\u00a0al. (2006) Quantitative measurement and visual assessment of ileal Crohn\u2019s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 55:1561\u20131567","journal-title":"Gut"},{"key":"9410_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ibd.20013","volume":"13","author":"PD Higgins","year":"2006","unstructured":"Higgins PD, Caoili E, Zimmermann M, et\u00a0al. (2006) Computed tomographic enterography adds information to clinical management in small bowel Crohn\u2019s disease. Inflamm Bowel Dis 13:262\u2013268","journal-title":"Inflamm Bowel Dis"},{"issue":"22","key":"9410_CR17","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMra072149","volume":"357","author":"DJ Brenner","year":"2007","unstructured":"Brenner DJ, Hall EJ (2007) Computed tomography\u2014an increasing source of radiation exposure. N Engl J Med 357(22): 2277\u20132284","journal-title":"N Engl J Med"},{"key":"9410_CR18","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(06)68748-5","volume":"367","author":"DR Martin","year":"2006","unstructured":"Martin DR, Semelka RC (2006) Health effects of ionising radiation from diagnostic CT. Lancet 367:1712\u20131714","journal-title":"Lancet"},{"key":"9410_CR19","doi-asserted-by":"crossref","first-page":"S448","DOI":"10.14309\/00000434-200609001-01148","volume":"101","author":"J Peloquin","year":"2006","unstructured":"Peloquin J, Pardi D, Sandborn W, et\u00a0al. (2006) Exposure to diagnostic ionizing radiation in a population-based cohort of patients with inflammatory bowel disease {abstract}. Am J Gastroenterol 101:S448\u2013S449","journal-title":"Am J Gastroenterol"},{"key":"9410_CR20","unstructured":"Siddiki H, Fletcher J, Bruining D, et\u00a0al. (2007) Performance of lower-dose CT enterography for detection of inflammatory bowel disease. RSNA abstract Chicago, Illinois SSA 10\u20132:254"},{"key":"9410_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1572-0241.2006.00506.x","volume":"101","author":"SL Triester","year":"2006","unstructured":"Triester SL, Leighton JA, Leontiadis GI, et\u00a0al. (2006) A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn\u2019s disease. Am J Gastroenterol 101:954\u2013964","journal-title":"Am J Gastroenterol"},{"key":"9410_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/00004836-199510000-00018","volume":"21","author":"U Kettritz","year":"1995","unstructured":"Kettritz U, Isaacs K, Warshauer DM, et\u00a0al. (1995) Crohn\u2019s disease. Pilot study comparing MRI of the abdomen with clinical evaluation. J Clin Gastroenterol 21:249\u2013253","journal-title":"J Clin Gastroenterol"},{"key":"9410_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S1542-3565(05)00853-0","volume":"3","author":"J Florie","year":"2005","unstructured":"Florie J, Horsthuis K, Hommes DW, et\u00a0al. (2005) Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn\u2019s disease. Clin Gastroenterol Hepatol 3:1221\u20131228","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9410_CR24","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/j.1572-0241.2005.00239.x","volume":"100","author":"CN Bernstein","year":"2005","unstructured":"Bernstein CN, Greenberg H, Boult I, et\u00a0al. (2005) A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn\u2019s disease. Am J Gastroenterol 100:2493\u20132502","journal-title":"Am J Gastroenterol"},{"key":"9410_CR25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, et\u00a0al. (1976) Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study. Gastroenterology 70:439\u2013444","journal-title":"Gastroenterology"},{"key":"9410_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1572-0241.2005.30487.x","volume":"100","author":"MB Frenz","year":"2005","unstructured":"Frenz MB, Dunckley P, Camporota L, et\u00a0al. (2005) Comparison between prospective and retrospective evaluation of Crohn\u2019s disease activity index. Am J Gastroenterol 100:1117\u20131120","journal-title":"Am J Gastroenterol"},{"key":"9410_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11938-005-0048-2","volume":"8","author":"S Shillon","year":"2005","unstructured":"Shillon S, Loftus E (2005) Medical therapy in Crohn\u2019s disease. Curr Treat Options Gastroenterol 8:19\u201330","journal-title":"Curr Treat Options Gastroenterol"},{"key":"9410_CR28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","volume":"77","author":"RW Summers","year":"1979","unstructured":"Summers RW, Switz DM, Sessions JT Jr, et\u00a0al. (1979) National Cooperative Crohn\u2019s Disease Study: results of drug treatment. Gastroenterology 77:847\u2013869","journal-title":"Gastroenterology"},{"key":"9410_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Stromberg U (2004) Oral Pentasa in the treatment of active Crohn\u2019s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2:379\u2013388","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9410_CR30","unstructured":"Akobeng AK, Gardener E (2005) Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s Disease. Cochrane Database Syst Rev CD003715"},{"key":"9410_CR31","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/gut.32.9.1071","volume":"32","author":"L Sutherland","year":"1991","unstructured":"Sutherland L, Singleton J, Sessions J, et\u00a0al. (1991) Double blind, placebo controlled trial of metronidazole in Crohn\u2019s disease. Gut 32:1071\u20131075","journal-title":"Gut"},{"key":"9410_CR32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0016-5085(82)80332-6","volume":"83","author":"LJ Brandt","year":"1982","unstructured":"Brandt LJ, Bernstein LH, Boley SJ, et\u00a0al. (1982) Metronidazole therapy for perineal Crohn\u2019s disease: a follow-up study. Gastroenterology 83:383\u2013387","journal-title":"Gastroenterology"},{"key":"9410_CR33","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","volume":"16","author":"SV Kane","year":"2002","unstructured":"Kane SV, Schoenfeld P, Sandborn WJ, et\u00a0al. (2002) The effectiveness of budesonide therapy for Crohn\u2019s disease. Aliment Pharmacol Ther 16:1509\u20131517","journal-title":"Aliment Pharmacol Ther"},{"key":"9410_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1056\/NEJM199808063390603","volume":"339","author":"OO Thomsen","year":"1998","unstructured":"Thomsen OO, Cortot A, Jewell D, et\u00a0al. (1998) A comparison of budesonide and mesalamine for active Crohn\u2019s disease. International Budesonide-Mesalamine Study Group. N Engl J Med 339:370\u2013374","journal-title":"N Engl J Med"},{"key":"9410_CR35","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","volume":"100","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Lofberg R, Feagan BG, et\u00a0al. (2005) Budesonide for maintenance of remission in patients with Crohn\u2019s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 100:1780\u20131787","journal-title":"Am J Gastroenterol"},{"key":"9410_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/gast.2001.26279","volume":"121","author":"WA Faubion Jr","year":"2001","unstructured":"Faubion WA Jr, Loftus EV Jr, Harmsen WS, et\u00a0al. (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255\u2013260","journal-title":"Gastroenterology"},{"key":"9410_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/gut.35.3.360","volume":"35","author":"P Munkholm","year":"1994","unstructured":"Munkholm P, Langholz E, Davidsen M, et\u00a0al. (1994) Frequency of glucocorticoid resistance and dependency in Crohn\u2019s disease. Gut 35:360\u2013362","journal-title":"Gut"},{"key":"9410_CR38","unstructured":"Pearson DC, May GR, Fick G, et\u00a0al. (1998) Azathioprine for maintaining remission of Crohn\u2019s disease. Cochrane Database Syst Rev CD000067"},{"key":"9410_CR39","doi-asserted-by":"crossref","unstructured":"Sandborn W, Sutherland L, Pearson D, et\u00a0al. (1998) Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev CD000545","DOI":"10.1002\/14651858.CD000545"},{"key":"9410_CR40","doi-asserted-by":"crossref","unstructured":"Alfadhli AAF, McDonald JWD, Feagan BG (2004) Methotrexate for induction of remission in refractory Crohn\u2019s disease. Cochrane Database Syst Rev CD003459","DOI":"10.1002\/14651858.CD003459.pub2"},{"key":"9410_CR41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et\u00a0al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med 337:1029\u20131035","journal-title":"N Engl J Med"},{"key":"9410_CR42","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et\u00a0al. (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomized trial. Lancet 359:1541\u20131549","journal-title":"Lancet"},{"key":"9410_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et\u00a0al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology 130:323\u2013333","journal-title":"Gastroenterology"},{"key":"9410_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"J-F Colombel","year":"2007","unstructured":"Colombel J-F, Sandborn WJ, Rutgeerts P, et\u00a0al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology 132:52\u201365","journal-title":"Gastroenterology"},{"key":"9410_CR45","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et\u00a0al. (1999) Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 340:1398\u20131405","journal-title":"N Engl J Med"},{"key":"9410_CR46","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et\u00a0al. (2004) Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 350:876\u2013885","journal-title":"N Engl J Med"},{"key":"9410_CR47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, et\u00a0al. (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829\u2013838","journal-title":"Ann Intern Med"},{"key":"9410_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, et\u00a0al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease. Gastroenterology 126:402\u2013413","journal-title":"Gastroenterology"},{"key":"9410_CR49","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","volume":"128","author":"GR Lichtenstein","year":"2005","unstructured":"Lichtenstein GR, Yan S, Bala M, et\u00a0al. (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn\u2019s disease. Gastroenterology 128:862\u2013869","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"9410_CR50","first-page":"A513","volume":"132","author":"B Feagan","year":"2007","unstructured":"Feagan B, Panaccione R, Sandborn W, et\u00a0al. (2007) An evaluation of adalimumab on the risk of hospitalization in patients with Crohn\u2019s disease, data from CHARM {abstract}. Gastroenterology 132(4 Suppl 2):A513","journal-title":"Gastroenterology"},{"key":"9410_CR51","first-page":"A-147","volume":"132","author":"S Schreiber","year":"2007","unstructured":"Schreiber S, Reinsich R, Colombel JF, et\u00a0al. (2007) Early Crohn\u2019s disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM {abstract}. Gastroenterology 132:A-147","journal-title":"Gastroenterology"},{"issue":"suppl II","key":"9410_CR52","first-page":"A131","volume":"55","author":"S Schreiber","year":"2006","unstructured":"Schreiber S, Colombel J, Panes J, et\u00a0al. (2006) Recent onset Crohn\u2019s disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: results from the analysis of the PRECISE III Study {abstract}. Gut 55(suppl II):A131","journal-title":"Gut"},{"key":"9410_CR53","first-page":"A108","volume":"130","author":"D Hommes","year":"2006","unstructured":"Hommes D, Baert F, van Assche G, et\u00a0al. (2006) The ideal management of Crohn\u2019s disease: top down versus step up strategies, a randomized controlled trial {abstract}. Gastroenterology 130:A108\u2013A109","journal-title":"Gastroenterology"},{"key":"9410_CR54","first-page":"A110","volume":"130","author":"G D\u2019Haens","year":"2006","unstructured":"D\u2019Haens G, Hommes D, Baert F, et\u00a0al. (2006) A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn\u2019s disease (abstract). Gastroenterology 130:A110","journal-title":"Gastroenterology"},{"key":"9410_CR55","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.gtc.2006.09.008","volume":"35","author":"JG Reddy","year":"2006","unstructured":"Reddy JG, Loftus EV Jr (2006) Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 35:837\u2013855","journal-title":"Gastroenterol Clin North Am"},{"key":"9410_CR56","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, et\u00a0al. (2005) Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 353:1912\u20131925","journal-title":"N Engl J Med"},{"key":"9410_CR57","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","volume":"132","author":"SR Targan","year":"2007","unstructured":"Targan SR, Feagan BG, Fedorak RN, et\u00a0al. (2007) Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial. Gastroenterology 132:1672\u20131683","journal-title":"Gastroenterology"},{"key":"9410_CR58","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, et\u00a0al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"9410_CR59","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/0016-5085(93)91068-S","volume":"105","author":"P Munkholm","year":"1993","unstructured":"Munkholm P, Langholz E, Davidsen M, et\u00a0al. (1993) Intestinal cancer risk and mortality in patients with Crohn\u2019s disease. Gastroenterology 105:1716\u20131723","journal-title":"Gastroenterology"},{"issue":"9 suppl","key":"9410_CR60","first-page":"S305","volume":"100","author":"S Dhillon","year":"2005","unstructured":"Dhillon S, Loftus EJ, Tremaine W, et\u00a0al. (2005) The natural history of surgery for Crohn\u2019s disease in a population-based cohort from Olmsted County, Minnesota {abstract}. Gastroenterology 100(9 suppl):S305","journal-title":"Gastroenterology"},{"key":"9410_CR61","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0140-6736(90)91889-I","volume":"336","author":"A Ekbom","year":"1990","unstructured":"Ekbom A, Helmick C, Zack M, et\u00a0al. (1990) Increased risk of large-bowel cancer in Crohn\u2019s disease with colonic involvement. Lancet 336:357\u2013359","journal-title":"Lancet"},{"key":"9410_CR62","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.gtc.2006.07.001","volume":"35","author":"DT Rubin","year":"2006","unstructured":"Rubin DT, Kavitt RT (2006) Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am 35:581\u2013604","journal-title":"Gastroenterol Clin North Am"},{"key":"9410_CR63","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1053\/j.gastro.2004.03.025","volume":"126","author":"SH Itzkowitz","year":"2004","unstructured":"Itzkowitz SH, Harpaz N (2004) Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126:1634\u20131648","journal-title":"Gastroenterology"},{"key":"9410_CR64","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/01.MIB.0000160811.76729.d5","volume":"11","author":"SH Itzkowitz","year":"2005","unstructured":"Itzkowitz SH, Present DH, Crohn\u2019s, Colitis Foundation of America Colon Cancer in IBDSG (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11:314\u2013321","journal-title":"Inflamm Bowel Dis"}],"container-title":["Abdominal Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-008-9410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00261-008-9410-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-008-9410-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-008-9410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T22:58:07Z","timestamp":1581980287000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00261-008-9410-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,21]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9410"],"URL":"https:\/\/doi.org\/10.1007\/s00261-008-9410-x","relation":{},"ISSN":["0942-8925","1432-0509"],"issn-type":[{"value":"0942-8925","type":"print"},{"value":"1432-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,21]]}}}